Vaxcyte, Inc. (PCVX)
61.18
+0.09
(+0.15%)
USD |
NASDAQ |
Aug 27, 16:00
61.18
0.00 (0.00%)
After-Hours: 20:00
Vaxcyte Debt to Equity Ratio : 0.0419 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0419 |
| March 31, 2026 | 0.0388 |
| December 31, 2025 | 0.0437 |
| September 30, 2025 | 0.0292 |
| June 30, 2025 | 0.028 |
| March 31, 2025 | 0.0273 |
| December 31, 2024 | 0.0215 |
| September 30, 2024 | 0.0082 |
| June 30, 2024 | 0.0129 |
| March 31, 2024 | 0.0138 |
| December 31, 2023 | 0.0236 |
| September 30, 2023 | 0.0098 |
| June 30, 2023 | 0.0106 |
| March 31, 2023 | 0.0176 |
| Date | Value |
|---|---|
| December 31, 2022 | 0.0188 |
| September 30, 2022 | 0.0551 |
| June 30, 2022 | 0.0579 |
| March 31, 2022 | 0.0623 |
| December 31, 2021 | 0.0591 |
| September 30, 2021 | 0.0038 |
| June 30, 2021 | 0.0029 |
| March 31, 2021 | 0.0035 |
| December 31, 2020 | 0.00 |
| September 30, 2020 | 0.00 |
| June 30, 2020 | 0.00 |
| March 31, 2020 | 0.00 |
| December 31, 2019 | 0.003 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Moderna, Inc. | 0.1904 |
| Arrowhead Pharmaceuticals, Inc. | 2.956 |
| Oncolytics Biotech, Inc. | -0.0726 |
| Sangamo Therapeutics, Inc. | -1.020 |
| Sarepta Therapeutics, Inc. | 0.6845 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 3.138B |
| Total Liabilities (Quarterly) | 380.21M |
| Shareholders Equity (Quarterly) | 2.758B |
| Current Ratio | 5.724 |
| Net Debt Paydown Yield | -0.07% |